Program
BB102
A development code. Also written as “BB102 tablet”.
Its studies are mostly in Carcinoma, Hepatocellular, led by Broadenbio.
Furthest: phase 2, since Nov 14, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Broadenbio | 22 open or running | phase 2since Nov 14, 2025 | Feb 6, 2024 | Dec 2026phase 1 · NCT06258408 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06258408 · 78 planned · China
- Nov 14, 2025Phase 2 study in Carcinoma, HepatocellularNCT07239986 · 60 planned · China
Ahead
- Dec 2026Primary completion: phase 1 study in Advanced Solid TumorNCT06258408
- Jun 2027Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07239986
TargetBeta
FGFR4 →read by rule
“This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma.”study text, by rule · the study
Other programs on FGFR4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| irpagratinibrule | Abbisko Cayman | phase 2 | 6 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07239986Carcinoma, Hepatocellular · China | 2 | Not yet recruiting | Jun 2027 | 60 |
| NCT06258408Advanced Solid Tumor · China | 1 | Recruiting | Dec 2026 | 78 |
How it is read
Names in the registry
- “BB102”, 1 entry
- “BB102 tablet”, 1 entry
Codes read as this program: BB102.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.